Preventing HIV transmission through antiretroviral treatment-mediated virologic suppression: Aspects of an emerging scientific agenda

Current Opinion in HIV and AIDS

Volumn 7, Issue 2, 2012, Pages 106-110

  Dieffenbach, Carl W ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

HIV testing; sero discordant; transmission; treatment as prevention; virus load; virus suppression

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CD4 LYMPHOCYTE COUNT; CLINICAL RESEARCH; DRUG FORMULATION; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH SERVICE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE HOMOSEXUAL; PATIENT CARE; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS SERODIAGNOSIS; ANTI-HIV AGENTS; BIOMEDICAL RESEARCH; DELIVERY OF HEALTH CARE, INTEGRATED; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; SEXUAL PARTNERS; VIRAL LOAD;

EID: 84857362333     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834f3f13     Document Type: Review

References (23)

1. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States: September 14, 2011. http://www.aidsinfo. nih. gov/guidelines/GuidelineDetail.aspx?GuidelineID=9&ClassID=2. AIDSinfo Web page.
2. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
3. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. J Am Med Assoc 2009; 301:2380-2382.
4. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
5. Branson BM, Handsfield HH, Lampe MA, et al. Centers for Disease Control and Prevention (CDC) Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1-17.
6. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
7. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis 2010; 51:725-731.
8. Ulett KB, Willig JH, Lin H-Y, et al. The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care and STDs 2009; 23:41-49.
9. Losina E, Bassett IV, Giddy J, et al. The 'ART' of linkage: pretreatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS ONE 2010; 5:e9538.
10. Gallant JE, Adimora AA, Carmichael JK, et al. Essential components of effective HIV care: a policy paper of the HIV Medicine Association and the Infectious Diseases Society of America and Ryan White Medical Providers Coalition. Clin Infect Dis 2011; 53:1043-1050.
11. Schwartlander B, Stover J, Hallett T, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 2011; 377:2031-2041.
12. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes and cost-effectiveness. CID 2009; 48:806-815.
13. Rotherman-Borus MJ, Swendeman D, Chovnick G, et al. The past, present and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Ann Rev Clin Psychol 2009; 5:143-167.
14. Hammer SM. Antiviral treatment as prevention. N Engl J Med 2011; 365:561-562.
15. Williams BG, Lima V, Gouws E. Modelling the impact of antiretroviral therapy on the epidemic of HIV. Cur HIV Res 2011; 9:367-382.
16. Severe P, Jean Juste MA, Ambroise A, et al. Early versus standard antiviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363:257-265.
17. Emery S, Neuhaus JA, Phillips AN, et al. Major Clinical Outcomes in antiretroviral therapy (ART)-naive participants and those not receiving ART at baseline in the SMART Study. J Infect Dis 2008; 197:1133-1144. (Pubitemid 351590049)
18. Strategic Timing of Antiretroviral Therapy (START); NCT00867048. http:// clinicaltrials.gov.
19. Johansson KA, Robberstad B, Norheim OF. Further benefits by early start to HIV treatment in low income countries: survival estimates of early versus deferred antiviral therapy. AIDS Res Ther 2010; 7:3.
20. Clayden P. HIV diagnostics pipeline. HIV Treatment Bul 2010; P25-P29.
21. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: October 14, 2011. http://www.aidsinfo.nih.gov/guidelines/ GuidelineDetail.aspx?GuidelineID7&ClassID1.
22. Baert L, van't Klooster G, Dries W, et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharmaceut Biopharmaceut 2009; 72:502-508.
23. McMichael AJ. HIV Vaccines. Ann Rev Immunol 2006; 24:227-255.